Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

about

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.

P2860

Q46129222-1309E00E-C8B5-40D1-868A-88926821ADAF

P2860

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

Item

http://www.wikidata.org/entity/Q40619773

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Assessment of HER2 status in p ...... s and prognostic implications.

@en

type

Item

label

Assessment of HER2 status in p ...... s and prognostic implications.

@en

prefLabel

Assessment of HER2 status in p ...... s and prognostic implications.

@en

P1476

Assessment of HER2 status in p ...... s and prognostic implications.

@en

P2093

Laura Giordano

http://www.w3.org/2001/XMLSchema#string

Luca Rubino

http://www.w3.org/2001/XMLSchema#string

Maria Chiara Tronconi

http://www.w3.org/2001/XMLSchema#string

Massimo Roncalli

http://www.w3.org/2001/XMLSchema#string

Paola Spaggiari

http://www.w3.org/2001/XMLSchema#string

Silvia Bozzarelli

http://www.w3.org/2001/XMLSchema#string

Uberto Fumagalli Romario

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

HER2 testing in gastric cancer: a practical approach

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients.

HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data.

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Clinicopathologic factors associated with HER2-positive gastric cancer and its impact on survival outcomes--a systematic review.

Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Predicting Anthracycline Benefit: TOP2A and CEP17-Not Only but Also.

P2888

s10120-016-0625-1

P304

428-437

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10120-016-0625-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-08-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27530622

http://www.w3.org/2001/XMLSchema#string

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

about

P2860

P2860

Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698